NCT03144999View on ClinicalTrials.gov

Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 29, 2017

Primary Completion Date

December 6, 2017

Study Completion Date

December 9, 2019

Conditions
Dry Age-related Macular Degeneration
Interventions
BIOLOGICAL

AAVCAGsCD59

AAVCAGsCD59 is administered as a single intravitreal injection in an office setting

Trial Locations (1)

02114

Ophthalmic Consultants of Boston, Boston

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03144999 - Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59 | Biotech Hunter | Biotech Hunter